What cannabis operators need to know this month

This Month in Focus

Three storylines worth your attention

1. The DEA is now the one pushing rescheduling

This is the shift most coverage buried. After years of dragging its feet on cannabis rescheduling, the DEA opened its administrative hearing this month by arguing in favor of moving cannabis to Schedule III. The agency's attorney told the tribunal the government would call two witnesses, a scientist and a medical practitioner, both to back the proposed rule. The pushback in the hearing room is coming from prohibitionists, not the DEA.

That is a meaningful posture change from the agency historically most responsible for stalling reform. Operators who have been discounting rescheduling as "it will never happen" should update their priors. It might still not happen on the timeline anyone wants, but the DEA is no longer the obstacle it was.

2. SAFE Banking is back on the table

Eight bipartisan House lawmakers reintroduced the SAFE Banking Act. If you have been in the industry long enough, this is a familiar dance: introduction, momentum, procedural roadblock, quiet death. That said, the political landscape has shifted. Rescheduling is in motion. Bipartisan cannabis reform is no longer unusual. Passage odds are still low, but the odds of meaningful floor action are higher than they have been in years.

Operators should not plan around passage. They should plan around what changes at their operation the day passage becomes plausible.

3. Cannabis companies gain bankruptcy access

Federal bankruptcy access has historically been off the table for cannabis operators because of the industry's federal legal status. That has now changed. It is a genuinely new option for financially distressed operators, and it also shifts the M&A landscape. Distressed sale dynamics change when Chapter 11 is a live alternative. Whether you are running a cash-tight operation or evaluating acquisition targets, understanding what bankruptcy access looks like in practice is worth an afternoon this month.

Worth Your Time

Six pieces that earned their place in your inbox

Regulation & Policy

Business & Markets

Operations & Compliance

Smart Take of the Month

The medical cannabis question no one is asking

Worth your time this month: MJBizDaily's "Will Rescheduling Revive Medical Cannabis?" The piece looks at a dynamic most rescheduling coverage skips: what happens to state-level medical markets if Schedule III opens up FDA-regulated medical cannabis products. Some medical programs have been in slow decline as adult-use expanded around them. Rescheduling could either accelerate that decline or resuscitate them, depending on how the FDA landscape develops.

The takeaway for operators: if your business model depends on the medical channel (patient counts, MMJ card renewals, therapeutic positioning), the coming 18 months could reshape your competitive landscape in ways the adult-use conversation is not covering. Worth thinking about now, not later.

On the Calendar

What's coming in the next 30 to 45 days

• Mid-July: Rescheduling hearings continue. Given the DEA's shift in posture, the more interesting watch is how prohibitionist witnesses build their record and how the administrative law judge handles the pro-rescheduling government.
• Late July: Q2 MSO earnings calls wind down. Compare same-store sales, margin trends, and capital allocation commentary against Q1 to see who is actually executing versus who is talking about it.
• Early August: Congressional recess begins. Any SAFE Banking momentum has to survive the break to matter. Watch what committee chairs say in their final week.
• Throughout August: State legislatures largely quiet. Good window to catch up on operational projects that get deprioritized when regulatory pressure spikes.
• Looking ahead: MJBizCon Las Vegas hotel deadlines tightening. If you have not booked and you are attending, do it this month. Last year's late bookers paid double.

One Thing to Try

Map your federal exposure

With rescheduling in active hearings, SAFE Banking reintroduced, and bankruptcy access newly available, several parts of your operation are exposed to federal policy shifts in ways they were not six months ago. Most operators have not sat down and mapped exactly which parts.

Spend one afternoon with your CFO or finance lead building a simple federal exposure map. Walk through your operation and label each item:

1. Where does the current federal status help us? (Barriers to competition, pricing power, incumbency advantages.)
2. Where does it hurt us? (280E, banking, insurance, capital access, listing restrictions.)
3. Which items in each column would meaningfully shift if rescheduling lands, SAFE Banking passes, or both?

You will end up with a page or two of specifics. That page becomes your scenario planning document for the rest of 2026, and it gives your senior team a shared vocabulary for talking about federal reform without either dismissing it or over-indexing on it.